SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study
Lučana Vicelić Čutura,
Milan Vujčić,
Davor Galušić,
Viktor Blaslov,
Marija Petrić,
Antonija Miljak,
Mirela Lozić,
Benjamin Benzon,
Katarina Vukojević,
Toni Bubić,
Nenad Kunac,
Danijela Zjačić Puljiz,
Ivana Kristina Delić Jukić,
Marinela Križanac,
Bernarda Lozić
Affiliations
Lučana Vicelić Čutura
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Milan Vujčić
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Davor Galušić
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Viktor Blaslov
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Marija Petrić
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Antonija Miljak
Department of Internal Medicine, Division of Haematology, University Hospital of Split, 21000 Split, Croatia
Mirela Lozić
Department of Biochemistry and Medical Chemistry, University of Split School of Medicine, 21000 Split, Croatia
Benjamin Benzon
Department of Anatomy Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia
Katarina Vukojević
Department of Anatomy Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia
Toni Bubić
Department of Pathology, Judicial Medicine, and Cytology, Division of Pathology, University Hospital of Split, 21000 Split, Croatia
Nenad Kunac
Department of Pathology, Judicial Medicine, and Cytology, Division of Pathology, University Hospital of Split, 21000 Split, Croatia
Danijela Zjačić Puljiz
Department of Internal Medicine, Division of Nephrology and Haemodialysis, University Hospital of Split, 21000 Split, Croatia
Ivana Kristina Delić Jukić
Department of Internal Medicine, Division of Nephrology and Haemodialysis, University Hospital of Split, 21000 Split, Croatia
Marinela Križanac
Department of Pediatric Disease, Division of Haematology, Oncology, Clinical Immunology and Genetics, University Hospital of Split, 21000 Split, Croatia
Bernarda Lozić
Department of Pediatric Disease, Division of Haematology, Oncology, Clinical Immunology and Genetics, University Hospital of Split, 21000 Split, Croatia
Hodgkin lymphoma (HL) is a rare lymphoid neoplasm in which Hodgkin/Reed–Stenberg (HRS) cells are admixed with a population of non-neoplastic inflammatory cells and fibrosis. Dysregulated expressions of cell cycle regulators and transcription factors have been proven as one of the hallmarks of HL. In that context, SATB1 and p16 have been reported as potential regulators of HL progression and survival. However, to date, no studies have assessed the expression levels of SATB1 and p16 in HL in Croatian patients or their prognostic values. Therefore, we investigated the expression pattern of SATB1 and p16 in paraffin-embedded lymph node biopsies using standard immunohistochemistry. We found that 21% of the patients stained positive for SATB1, while 15% of the patients displayed positive staining for p16. Furthermore, we aimed to understand the prognostic value of each protein through the analysis of the overall survival (OS) and progression-free survival (PFS). SATB1 showed a significantly positive correlation with better OS and PFS, while p16 expression had no impact. Interestingly, when patients were stratified by a combination of the two studied markers, we found that patients in the SATB1+/p16- group tended to have the best prognosis in HL, according to statistical significance. In conclusion, SATB1 and p16 might be potentially useful as diagnostic and prognostic markers for HL.
